Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|FLT3 exon 14 ins FLT3 D835V||hematologic cancer||sensitive||KX2-391||Preclinical - Cell culture||Actionable||In a preclinical study, KX2-391 treatment inhibited cell viability and decreased downstream signaling in cells expressing a FLT3-ITD mutation with FLT3 D835V in culture (PMID: 34217323).||34217323|
|FLT3 exon 14 ins FLT3 D835V||Advanced Solid Tumor||resistant||Pexidartinib||Preclinical||Actionable||In a preclinical study, transformed cells expressing FLT3-ITD along with FLT3 D835V were resistant to PLX3397 in culture (PMID: 25847190).||25847190|
|FLT3 exon 14 ins FLT3 D835V||Advanced Solid Tumor||sensitive||MRX-2843||Preclinical - Cell culture||Actionable||In a preclinical study, MRX-2843 inhibited Flt3 signaling, resulted in growth inhibition in Quizartinib (AC220)-resistant transformed cells over expressing both FLT3 internal tandem duplication (ITD) and D835V in culture (PMID: 27158668).||27158668|
|FLT3 exon 14 ins FLT3 D835V||hematologic cancer||predicted - sensitive||HQP1351||Preclinical - Cell culture||Actionable||In a preclinical study, transformed cells expressing FLT3-ITD and FLT3 D835V demonstrated decreased proliferation in response to GZD824 (HQP1351) in culture, but were less sensitive to treatment than cells co-expressing FLT3-ITD with other FLT3 kinase domain mutations (PMID: 32247263).||32247263|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|